Objectives: To investigate the impact of plasmid-borne oqxAB genes on the development of fluoroquinolone resistance, mutations and bacterial fitness in Escherichia coli.
Introduction
Quinolones are widely used for treating human and animal infections, and the rise in global resistance to quinolones poses a great challenge to clinical treatment and public health, given the possible transmission of fluoroquinolone resistance from animals to humans. 1 The primary mechanisms of resistance to quinolones are chromosome-encoded, mainly including mutations in DNA gyrase and topoisomerase IV, as well as overexpression of drug efflux systems and decreased outer membrane permeability. 2 Moreover, since the emergence of plasmid-mediated quinolone resistance (PMQR) in 1998, 3 at least three types of PMQR mechanisms have been commonly detected in Enterobacteriaceae to date, including Qnr proteins, the aminoglycoside acetyltransferase AAC(6 0 )-Ib-cr, and the efflux pumps QepA and OqxAB. [4] [5] [6] [7] Although PMQR determinants can only confer low-level resistance to fluoroquinolones, their horizontal and worldwide spread among Enterobacteriaceae may facilitate the emergence of fluoroquinolone resistance. 1 A previous study showed that qnrS1 increased fitness, whereas qnrA1 decreased fitness when combined with chromosomal mutations in Escherichia coli, suggesting a potential driving force in the development of resistance to fluoroquinolones. 8 The qepA2 gene could confer a clinical level of fluoroquinolone resistance when combined with two or three chromosomal mutations, and was associated with a biological cost when combined with mutations in gyrA and/or parC in E. coli, J Antimicrob Chemother 2017; 72: 1293-1302 doi:10.1093/jac/dkw576 Advance Access publication 4 February 2017 which could be compensated by an additional deletion of marR. 9 Furthermore, aac(6 0 )-Ib-cr combined with three or four chromosomal mutations could induce a clinical level of ciprofloxacin and norfloxacin resistance in E. coli. 10 OqxAB, as a member of the resistance-nodulation-division family of efflux pumps, is encoded by the genes oqxA and oqxB located in the same operon. 11 OqxAB mediates the resistance or reduced susceptibility toward multiple agents, including quinoxalines, chloramphenicol, trimethoprim and quinolones. 7, 12 Recently, oqxAB genes were detected to be prevalent among E. coli and Salmonella isolates from animals, particularly pigs, as well as from animal-derived food and human clinics in China. [13] [14] [15] [16] [17] The presence of plasmids carrying oqxAB increases the mutation prevention concentration (MPC) of ciprofloxacin and resistance to ciprofloxacin only requires a single gyrA mutation, which facilitates the selection of ciprofloxacin-resistant Salmonella typhimurium. 16 However, the contribution of oqxAB to the development of fluoroquinolone resistance is still unclear. In this study, we investigated the association of oqxAB with fluoroquinolone resistance, chromosomal mutations and bacterial fitness in E. coli to provide new insights into the contribution of plasmid-mediated oqxAB for the evolution of fluoroquinolone resistance.
Materials and methods

Bacterial strains
Fifteen oqxAB-positive E. coli strains (negative for other PMQR determinants) obtained from food animals, companion animals, healthy volunteers and retail meat from two different geographic areas of China in 2010-11 were included in this study. 13 The constructed isolate E. coli DH5a/pMD18-T::oqxAB was described previously. 18 
Conjugation/transformation experiments and plasmid characterization
Conjugation experiments were performed using streptomycin-resistant E. coli C600 as the recipient strain following a previously reported protocol with minor modifications. 19 Transconjugants were selected on MacConkey agar plates containing olaquindox (16 mg/L) and streptomycin (3000 mg/L). Conjugation transfer of the plasmids pHNGC59 and pHNFD436 into E. coli C600 was re-performed using florfenicol (32 mg/L) and streptomycin (3000 mg/L) for the selection of transconjugants.
Plasmid DNA was extracted using the E.Z.N.A. Plasmid DNA Midi Kit (Omega, Norcross, GA, USA) and transferred into the E. coli recipient strain TOP10 (streptomycin-resistant) by chemical transformation. Transformants were selected using 12 mg/L olaquindox or 32 mg/L ampicillin (only used to select the constructed plasmid pMD18-T::oqxAB).
The presence of oqxAB in transconjugants/transformants was further confirmed by PCR and sequencing. The presence of the floR, tetA, sul1 and sul2 genes was detected using the primer pairs listed in Table S1 (available as Supplementary data at JAC Online). After transfer, oqxAB-carrying plasmids were characterized by PCR-based replicon typing (PBRT) as described previously, 20 and the size was determined with S1-PFGE and Southern blot hybridization. 21 The genetic context surrounding oqxAB was determined by PCR mapping using the primers listed in Table S2 .
Antimicrobial susceptibility testing and MPC
The transformants, their corresponding wild-type oqxAB-positive isolates and the recipient strain for E. coli TOP10 were tested for their MICs of ampicillin, cefotaxime, gentamicin, amikacin, neomycin, streptomycin, tetracycline, chloramphenicol, florfenicol, ciprofloxacin, olaquindox and sulfamethoxazole/trimethoprim using the agar dilution method recommended by the VET01-S2 22 and M100-S25 23 guidelines of the CLSI (Wayne, PA, USA). The results were interpreted according to EUCAST clinical breakpoints. 24 The E. coli reference strain ATCC 25922 was used for quality control. The MPCs of ciprofloxacin for E. coli TOP10 and the corresponding transformants were determined as previously described. 8 Plasmid stability and growth curve
To investigate plasmid stability, all transformants were maintained for 4 days in daily refreshed (100-fold dilution) LB broth without antibiotic selection, and viable counts were determined at 96 h by plating aliquots on to MacConkey agar. Colonies from each viable count were replica-plated on to MacConkey agar plates containing 12 mg/L of olaquindox or 32 mg/L ampicillin, and were randomly selected to confirm the presence of oqxAB by PCR.
The growth curve of all transformants and E. coli TOP10 was determined in LB broth at 37 C and 200 rpm. After overnight culture in LB broth, bacterial suspensions were diluted to an optical density at 600 nm (OD 600 ) of 0.02 in 30 mL fresh LB medium, flasks were incubated for 11 h and the OD 600 of the cultures were measured every hour using a Multiskan FC Microplate Photometer (Thermo Fisher Scientific, Waltham, MA, USA). Experiments were performed in triplicate.
Development of resistance by serial passages
Serial passages were performed in Mueller-Hinton (MH) broth in the presence of a 0.5% MIC of ciprofloxacin inoculated at 37 C and 200 rpm for 12-14 h. Briefly, an inoculum of the 0.5-fold MIC culture was taken and adjusted to 0.5 McFarland units with 0.85% sterile saline solution to determine the MIC against ciprofloxacin by the broth macrodilution method. According to the MIC, 100 lL of the former passaged culture was inoculated in 0.5% MIC of ciprofloxacin again. This process was repeated for each of the 20 passages. To obtain individual colonies for further analysis, each passaged culture grown in MH broth was plated on to MacConkey agar without antibiotics and 10 or 20 colonies were randomly selected and tested for their susceptibility to ciprofloxacin, enrofloxacin and nalidixic acid by the agar dilution method.
PCR amplification and DNA sequencing
The gyrA, gyrB, parC and parE genes containing the quinolone-resistance determining regions and the full-length nucleotide sequences of acrR, soxS, soxR, marR, marA and marB in mutants were determined by PCR and sequencing using the primer pairs listed in Table S1 . Gene mutations in the test strains were identified by comparison to the E. coli strain K12 substrain MG1655 (accession number U00096).
Growth competition assays
E. coli TOP10 was used as the standard reference strain against the two transformants and 24 mutants chosen on the basis of differences in the MIC of ciprofloxacin and/or mutants. The growth competition experiments were carried out as previously described with minor modifications. 8, 25 At 0 and 48 h, the total number of viable cells was determined by plating appropriate dilutions on to antibiotic-free MacConkey agar. Colonies from each viable count collected at 48 h were replica-plated on MacConkey agar containing 12 mg/L olaquindox or nalidixic acid to determine the number of resistant cells. All competition experiments were performed at least in triplicate. The relative fitness (RF) was calculated as follows: RF " (log 10 S1 d1 -log 10 S1 d0 )/(log 10 S2 d1 -log 10 S2 d0 ), S1 d1 and S1 d0 are the respective cfu densities of the transformants or mutant strains at 48 h and 0 h, and S2 d1 and S2 d0 are the equivalent values for the control strain.
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In vivo fitness in a mouse model of systemic infection
In vivo fitness was assessed by a competition experiment using a systemic infection mouse model. 26 Each individual competition assay was performed using six male NIH mice weighing 14-16 g. The mice were sacrificed by cervical dislocation 24 h after inoculation and the spleens were aseptically extracted and homogenized in 1 mL of sterile saline solution. The cfu per strain were determined as described for the in vitro growth competition experiments. Competitive index values were calculated as the geometric mean of the ratio of mutant/control bacteria isolated from the spleen tissue of six mice per experiment, normalized to the ratio at the time of inoculation. 27 Animals were purchased from the Guangdong Medical Laboratory Animal Center.
Ethics
The experimental protocol was approved by the Institutional Animal Care and Use Committee at the South China Agricultural University, and performed in accordance with the approved guidelines for the care and use of laboratory animals by the South China Agricultural University.
Nucleotide sequence accession numbers
The nucleotide sequences of an 8600 and 8587 bp fragment of plasmids pHNFD436 and pHNGC59 were deposited in GenBank under the accession numbers KX602252 and KX602253, respectively.
Results
Characterization of OqxAB-encoding plasmids
Plasmids from E. coli strain GAC59 of chicken origin, FKD436F of duck origin, as well as DH5a/pMD18-T::oqxAB, were successfully transferred to E. coli TOP10 through transformation, designated as pHNGC59, pHNFD436 and pMD18T-oqxAB, respectively. The results of S1-PFGE and Southern hybridization performed on the transformants TOP10:pHNGC59 and TOP10:pHNFD436 confirmed that oqxAB genes were located on a single plasmid with different sizes (Table 1 ). The two plasmids exhibited distinct restriction fragment length polymorphism patterns using the EcoRI restriction enzyme (data not shown); pHNGC59 belonged to the IncF type, but the replicon type for pHNFD436 could not be determined with the PBRT method.
An 8587 and 8600 bp oqxAB-containing fragment was obtained from pHNGC59 and pHNFD436, respectively. Sequencing results showed that oqxAB was flanked by two IS26 elements in the same orientation, which are believed to play an important role in gene transmission. 28 The oqxAB-carrying regions showed 99% identity to the corresponding region of plasmids pHXY0908 (accession no. KM877269) from an S. typhimurium strain of chicken origin in Guangdong, China; pOLA52 (EU370913) of porcine E. coli in Denmark; 10 pHK0653 (KT334335) from a clinical S. typhimurium isolate in Hong Kong, China; and pHNSHP45-2 (KU341381) from a porcine colistin-resistant E. coli isolate in Shanghai, China 29 ( Figure S1 ).
Antimicrobial resistance and resistance determinants
The results of antimicrobial susceptibility testing are shown in Table 1 . The acquisition of oqxAB genes caused resistance to chloramphenicol and increased the MICs of ciprofloxacin, olaquindox, florfenicol and sulfamethoxazole/trimethoprim compared with those of E. coli TOP10:pMD18T, supporting the function of the OqxAB efflux pump. In addition, TOP10:pHNGC59 and TOP10:pHNFD436 were resistant to ampicillin, tetracycline, chloramphenicol, florfenicol and sulfamethoxazole/trimethoprim, and showed elevated MICs for ciprofloxacin (4-8-fold) and olaquindox (16-32-fold). The transformant TOP10:pHNFD436 also exhibited resistance to neomycin, and the MIC of cefotaxime increased 4-fold (0.25 mg/L). The resistance genes floR, sul2 and tetA were also confirmed to be located on both plasmids pHNGC59 and pHNFD436. Interestingly, two oqxAB-carrying transconjugants were successfully obtained from GAC59 and FKD436F when conjugation experiments were re-performed under selection with 32 mg/L florfenicol, although both carried multiple plasmids and were not studied further.
Plasmid stability, growth curves and MPC
The oqxAB genes and oqxAB-carrying plasmids contributed to a 4-8-fold increase of the ciprofloxacin MIC in E. coli. However, TOP10/pMD18-T::oqxAB showed much weaker growth, and stability experiments performed in the absence of antibiotics Figure S2 ). Thus, the transformants TOP10:pHNGC59 and TOP10:pHNFD436 were selected for further investigation.
To assess the contribution of an OqxAB-encoding plasmid to fluoroquinolone resistance mutation development, the MPCs of ciprofloxacin were determined. As shown in Table 1 , the MPC values of ciprofloxacin for the two transformants were 8-and 16-fold higher, respectively, than that of the recipient strain E. coli TOP10. The MPC/MIC values of both transformants were 2-fold higher than those of E. coli TOP10.
Development of resistance to ciprofloxacin by serial passages and mutation identification
Changes in the MICs of ciprofloxacin for TOP10 and the corresponding transformants with serial passages are shown in Figure 1 and Table 2 . The first MIC increase (8-fold) occurred after three passages for TOP10 but after only two passages for both transformants. Similarly, the second 8-fold MIC increase appeared after 16 passages for TOP10 but after only 9 and 10 passages for TOP10:pHNFD436 and TOP10:pHNGC59, respectively. Furthermore, the two transformants developed resistance to ciprofloxacin after 12 or 16 passages, respectively, whereas TOP10 was still susceptible after 20 passages. Therefore, OqxAB-encoding plasmids led to much faster development of resistance to fluoroquinolones; the MIC of ciprofloxacin increased 128-fold for TOP10 (0.25 mg/L) and 256-fold for the transformants (2 and 4 mg/L) after 20 passages.
Mutations within gyrA were distributed at codons 87 (D87Y or N) and 83 (novel mutation DS83) in the two transformants, whereas the mutation A119E dominated in the TOP10 mutants (Table 2) . Furthermore, new mutations of gyrB (A468P or F458V) were identified after two passages of the two transformants with 8-fold increased MICs of ciprofloxacin, but were not detected among the TOP10 mutants. In addition, the mutation I444F of parE was newly identified and only detected after 14 passages of TOP10:pHNFD436. Deletion of 15 nucleotides within soxR was observed after 16 passages of TOP10:pHNGC59 and a similar six-nucleotide deletion of soxR was observed after 19 passages (1 of 5) and 20 passages (3 of 10) in TOP10 mutants. A marR mutation (E31stop) only appeared in the last step of the ciprofloxacin MIC increase for TOP10 (Table 2) . Strikingly, none of the mutants harboured a mutation in the parC gene.
In vitro bacterial fitness of resistant isogenic strains
The gyrA mutation DS83 only appeared after five and six passages for TOP10:pHNFD436 and TOP10:pHNGC59, and then quickly disappeared, suggesting that this mutation may be associated with a great fitness cost and was readily replaced by other mutants with higher fitness. To test this hypothesis, growth competition experiments were performed in vitro.
The estimated fitness values demonstrated that gyrA DS83 mutants had a substantial biological cost (49%-51%). Individuals in the population with a different mutation (gyrB F458V or A468P) showed relatively higher fitness, but also exhibited a fitness cost compared with E. coli strain TOP10, thus lending support to our hypothesis of competition between mutants (Table 3 ). The FKD-7D2 mutants showed higher fitness than FKD-7D1 mutants, with a different substitution at position 87 of GyrA, although both exhibited the same MICs to the tested antimicrobials. A similar result was observed for mutants FKD-10D11 and FKD-10D17 (Table 3) , indicating that the gyrA mutation D87Y has a fitness advantage over D87N and may be responsible for the disappearance of the gyrA D87N mutation after 12 passages.
The acquisition of the OqxAB-encoding plasmids pHNGC59 and pHNFD436 caused apparently reduced fitness (13% and 24%, respectively) ( Table 3 ). The mutation F458V in gyrB alone further reduced fitness for TOP10:pHNFD436; however, increased fitness was observed when combined with other mutations, with some mutants actually showing a biological advantage (4.5%-11.9%, Table 3 ). In TOP10:pHNGC59, the mutation gyrB A468P alone slightly impacted the fitness, whereas fitness was enhanced when combined with gyrA D87Y, although none of the selected mutants showed a significant biological benefit (Table 3) . Furthermore, the mutant TOP10-5D1 (gyrA A119E) had significantly increased fitness compared with the mutant TOP10-5D5 without a gyrA mutation, although both mutants showed the same MICs for the tested agents. Surprisingly, the mutant TOP10-16D1 (gyrA A119E) displayed the highest fitness value (2.034) with a 64-fold increase in the MIC of ciprofloxacin, suggesting that other undetected mutations may contribute to the increased MIC and bacterial fitness (Table 3) .
In vivo bacterial fitness in a mouse infection model
To investigate further the relative fitness from a clinical perspective, the two transformants and the mutants showing reduced (GAC-5D11, GAC-8D1 and FKD-5D19) and enhanced (FKD-10D11 and FKD-15D4) fitness in vitro were selected to compete against E. coli TOP10 in the mouse model of systemic infection. GAC-5D11 and FKD-5D19 with the mutation gyrA DS83 displayed a significant fitness cost in vivo (competitive index of 0.141 and 0.087, respectively; Table 4 and Figure 2 ). The in vivo fitness results for FKD-10D11, FKD-15D4 and GAC-8D were also in agreement with those observed in vitro. However, although plasmids pHNGC59 and pHNFD436 were associated with a biological cost in vitro, they showed biological benefits in the spleen (Table 4 and Figure 2 ).
Discussion
In this study, we attempted to understand better the interplay between OqxAB-encoding plasmids and fluoroquinolone resistance, as well as their evolutionary dynamics. We used the constructed E. coli strain TOP10:pMD18T-oqxAB to exclude the interference of other complex structures in natural plasmids that have been observed in previous studies on plasmid-borne qnr and qepA. 8, 9 Unfortunately, this constructed strain showed much weaker growth, as previously described in S. typhimurium, 15 and could not be stably maintained. PMQR-positive plasmids have been widely used to assess the contribution of qnr, oqxAB and aac(6 0 )-Ib-cr to resistance. 16, 30 The potential interactions of oqxAB with other resistance genes such as floR and bla CTX-M-14 located on the same plasmid 29 Plasmid-borne oqxAB accelerates fluoroquinolone resistance in E. coli (10) gyrA D87Y ! gyrB F458V (13) gyrA D87N ! gyrB F458V (7) 
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different natural oqxAB-encoding plasmids were obtained for further investigation of the contribution of this gene through serial passages with a 0.5-fold MIC of ciprofloxacin. This approach differs from the typical stepwise selection of mutants on plates containing antibiotics. 30, 31 Acquisition of the OqxAB-encoding plasmid directly enhanced the MIC of ciprofloxacin by 4-8-fold, with some susceptibility remaining and an apparent fitness cost. Comparison to the E. coli strain TOP10 showed that oqxAB appears to facilitate the development of fluoroquinolone resistance, as the MIC of ciprofloxacin for the two transformants with oqxAB-bearing plasmids increased much faster than that of E. coli TOP10, particularly before 16 passages. Furthermore, the mutations also showed complexity and diversity during resistance development. In OqxAB-positive strains, mutations within gyrB occurred first, followed by mutations in gyrA at DS83, D87Y or D87N. These findings are in agreement with previous reports showing that the most frequent substitutions occur at positions 83 and 87 in GyrA in E. coli. [32] [33] [34] In TOP10 mutants, without the OqxAB-encoding plasmid, substitution at position 119 in GyrA, which lies outside of the quinolone-resistance determining region, was observed, and no gyrB mutations were detected. Although a single mutation in gyrB increased the MIC of ciprofloxacin, the gyrB mutations detected were associated with a fitness cost. This might explain the relative rarity of gyrB mutations reported in clinical strains, although the cost of mutations in gyrB could be compensated by additional gyrA mutations. Surprisingly, the enhancement of the MIC of ciprofloxacin caused by mutations in gyrA at codon 87 in our study was somewhat limited, suggesting that this substitution might have a fitness benefit and could function as a compensatory mutation. Notably, mutants with different MICs to the tested antimicrobials had the same mutations, indicating that some unknown mutations may account for the changes.
Although both oqxAB-bearing plasmids showed a fitness cost, they could be stably maintained without selective pressure and rarely affected the growth of the recipient strains. Additionally, the presence of plasmid-borne oqxAB accelerated the evolution of fluoroquinolone resistance, and the biological cost could be compensated by two or more additional chromosomal mutations conferring reduced susceptibility to fluoroquinolones. Taken together, these findings could explain the generally high prevalence of oqxAB in E. coli. Interestingly, the two transformants did not evolve at the same rate, and showed distinct mutations during serial passages. This may be due to specific differences between the plasmids pHNFD436 and pHNGC59. Nevertheless, the genetic Plasmid-borne oqxAB accelerates fluoroquinolone resistance in E. coli JAC backgrounds of oqxAB were identical, highlighting the complexity of developing resistance to fluoroquinolones. This is consistent with the multiple evolutionary trajectories reported for fluoroquinolone resistance in parallel Streptococcus pneumoniae populations. 35 Interestingly, in our study, some mutations appeared for several passages and then disappeared, such as DS83 and D87N in gyrA. The results of RF assessment can provide insight into this replacement. A similar phenomenon was observed in S. pneumoniae, 35 indicating that multiple genotypes compete so that the more beneficial mutations ultimately become dominant in the population.
Notably, E. coli TOP10 (recA1 mutation) inhibits SOS induction, which plays an important role in the development of ciprofloxacin resistance in E. coli. 36, 37 Given the deficiency of the SOS system in E. coli TOP10 and two corresponding transformants, our study may not demonstrate exactly the natural dynamics of response to fluoroquinolones. Further studies will be needed to investigate the impact of plasmid-borne oqxAB genes on the development of fluoroquinolone resistance in E. coli with the normal SOS system.
In conclusion, although acquisition of the OqxAB-encoding plasmid has a fitness cost, it appears to facilitate the rapid Mean fitness relative to E. coli TOP10. Standard deviation (in parentheses) measured in pairwise competition experiments. An RF score .1 indicated that the mutant strain had a selective advantage over the control strain, whereas a score ,1 indicated a fitness cost. Wang et al.
development of fluoroquinolone resistance, and the cost could be compensated by two additional chromosomal mutations. The identification of novel mutations and competition among mutations during the development of resistance provides a solid basis toward understanding the mechanism of resistance and the contribution of OqxAB to this process.
